Skip to: Content
Skip to: Site Navigation
Skip to: Search
MONDAY, NOVEMBER 23, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: prasugrel

prasugrel stories: 2 news summaries

 Novartis Acquires Plavix Rival 

Novartis acquires worldwide rights from a San Francisco biopharmaceutical firm

Feb 12, 09 8:22 AM CST
(Newser) - Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion... More »

MORE ABOUT:
pharmaceutical companies • Eli Lilly • Lipitor • prasugrel • Plavix • Bristol Myers Squibb • Novartis AG • Portola Pharmaceuticals • elinogrel

New Blood Thinner Tops Plavix in Trials

But prasugrel also adds risk of bleeding to death

Nov 5, 07 9:00 AM CST
(Newser) - An experimental new blood-thinner looks like real competition for top-selling anti-clotting drug Plavix, after proving more effective at preventing heart attacks, strokes, and heart-related death in a recent trial, the AP reports. But “there is a price to pay” for increased effectiveness, wrote one doctor—the new drug caused... More »

MORE ABOUT:
medicine • FDA • drugs • heart disease • heart • heart attack • prasugrel • Plavix • blood thinner

2 Stories


from our news partners